

NB: this is a summary translation of the press release
original drafted in Japanese for the disclosure
required in compliance with the TSE regulations.

Jun 14, 2021

Oncolys BioPharma Inc.

Announcement of the effect of OBP-2011 against SARS and MERS

Oncolys BioPharma Inc. (hereafter, "Oncolys") announced that its candidate for Covid -19 therapeutic agent (OBP-2011) was found to show an effect for SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome) in vitro experiment.

OBP-2011 has suggested to be effective for SARS-CoV-2 variants in vitro experiment as disclosed a press release on March 23, 2021. These results of the experiment suggest that OBP-2011 can potentially be effective in the treatment of early-stage infected people not only with SARS-COV-2 variants, but with various coronaviruses that would cause global pandemic in the future.

Oncolys is making comprehensive effort to treat Covid-19 and we are aiming to step up to clinical stage in 2022.

Ends

###

About Oncolys BioPharma Inc.

Oncolys BioPharma develops novel cancer therapeutics and diagnostic products using gene modified viral technologies and aims to contribute to fulfill unmet medical needs for cancer and severe infectious diseases. Especially in oncology area, we utilize technology platform for oncolytic virus and develop Telomelysin and its next-generations for cancer treatment and TelomeScan for early detection of cancer and recurrence monitoring after surgery. We have established broad range of product pipeline to cover early detection of cancer, early treatment of local cancer, post-operative examination, and treatment of metastatic cancer. For more information, please visit <http://www.oncolys.com/en/>

Oncolys BioPharma Inc.

Email: oncolys_information@oncolys.com